SWOG clinical trial number
C10403

An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)

Closed
Phase
Abbreviated Title
Phase II Adolescent/Young Adult with Untreated ALL
Status Notes
Permanent Closure Effective 9/14/12

Activated
01/15/2008
Closed
09/14/2012
Participants
NCORP, Members, Medical Oncologists, Pathologists, Affiliates

Research committees

Leukemia

Treatment

Cytosine Arabinoside Cyclophosphamide Dexamethasone Vincristine 6-Mercaptopurine 6-Thioguanine Allopurinol Daunomycin Doxorubicin Leucovorin Calcium Methotrexate Trimethoprim sulfa PEG-L-Asparaginase

Other Clinical Trials

CTSU/A042001
SWOG Clinical Trial Number

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
S1925
SWOG Clinical Trial Number

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.

Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
58% Accrual
Accrual
58%
Open
Phase
CTSU/AALL1821
SWOG Clinical Trial Number

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse

Research Committee(s)
Leukemia
Activated
12/04/2020
Open